Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Phase 2 DMT Stroke Study Design Finalized

<< Previous

Bullboard Posts

Next >>

Comment by Whalewatcher1on Aug 09, 2023 7:08pm

179 Views

Post# 35580684

RE:RE:Phase 2 DMT Stroke Study Design Finalized

This company needs new management. A reset on strategy, pick an indication and finally run a properly designed trial. Seemed they had positive trend data for chronic cough. Chris keeps using Bellus as a comparable. How about run the company like Bellus by bringing on board people on management team who know how to do real drug development, focus and do one trial right. Why is this so hard. Need a new board who can give the direction as well. Good luck to all

<< Previous

Bullboard Posts

Next >>

As AI expands, where can investors look for strong growth?